Treating osteogenesis imperfecta by inhibiting the PRC2 complex

The goal of this proposal is to develop a new strategy for skeletal regeneration in patients who have osteogenesis imperfecta (OI) or brittle bone disease using epigenetics regulators that alter gene expression. We have shown that inhibiting a epigenetic regulator, PCR2, increases bone formation in normal mice and will determine if this also occurs in OI mice. We will also investigate if a small molecule that inhibits the PRC2 complex can also increase bone formation in OI mice and cells from OI patients.